Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...
Sarepta Therapeutics Inc. shares plunged after a trial designed to confirm the benefits of two of its older drugs failed to show clear patient improvement, raising questions about their future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback